Skip to main content
  • Nederlands
    • English
    • Français

Home
  • Inloggen
  • Therapeutische domeinen
    • Cardiologie
      • ASCVD
      • Hartfalen
    • Dermatologie
      • Netelroos
    • Hematologie
      • ITP
    • Luchtwegen
    • Neurologie
      • Multiple sclerose
    • Oncologie
      • Borstkanker
      • Prostate Cancer (mCRPC)
    • Oogheelkunde
      • Netvliesaandoeningen
    • Reumatologie
  • Congressen en evenementen
    • Cardiologie
      • BSC
      • ESC
    • Dermatologie
      • EADV
      • Sharing is Caring
    • Hematologie
      • ASH
      • EHA
      • ESH
    • Neurologie
      • CMSC
      • EAN
      • ECTRIMS
    • Oncologie
      • ASCO
      • EBCC
      • ESMO
      • SABCS
    • Reumatologie
      • Sharing is Caring
  • Contact

Popular Search

  • improved
  • improving
  • aimovig
  • migration
  • migraine

Recent News

RLTech and Nurse Academy
IMPACT event: Innovation and Multidisciplinary care with Pluvicto for Advanced mCRPC patients
Page protected by password
Search
  • Diagnostics

    The importance of early testing and early treatment

    To choose a suitable treatment for melanoma it is important to make the right diagnosis as soon as possible and to start treatment. On this page you can read more about the diagnosis for...

    Twitter Linkedin Facebook Pinterest Google plus
  • Safety Profile - Entresto

    ENTRESTO ® demonstrated comparable safety and tolerability vs Enalapril
    Twitter Linkedin Facebook Pinterest Google plus
  • Dosing - Entresto

    Dose regimen Oral use Twice daily dose. Can be taken with or without food; The tablets must be swallowed with a glass of water. Tablet strength makes interim dose adjustment easy. If a dose is missed, the patient should take the next...
    Twitter Linkedin Facebook Pinterest Google plus
  • Reimbursement / eHealth - Entresto

    Entresto ® is reimbursed for the treatment of adult patients with chronic heart failure with reduced ejection fraction in Belgium.

    Twitter Linkedin Facebook Pinterest Google plus
  • PIONEER-HF

    The recently presented PIONEER-HF studies the efficacy and safety of initiating ENTRESTO compared to enalapril prior to discharge after hospitalization for an acute decompensated heart failure episode. 1 The results of PIONEER-HF...

    Twitter Linkedin Facebook Pinterest Google plus
  • Efficacy - Entresto

    ENTRESTO ® achieved superior outcomes vs Enalapril in the largest trial ever conducted in HF
    Twitter Linkedin Facebook Pinterest Google plus
  • Dosing

    Twitter Linkedin Facebook Pinterest Google plus
  • Mechanism of Action

    TPO is the main cytokine involved in regulation of megakaryopoiesis and platelet production, and is the endogenous ligand for the TPO-R.
    Twitter Linkedin Facebook Pinterest Google plus
  • Patient Resources

    Twitter Linkedin Facebook Pinterest Google plus
  • Mechanism of Action - Entresto

    Sacubitril/valsartan, a first-in-class ARNI, delivers simultaneous inhibition of neprilysin and blockade of the AT1 receptor. Sacubitril/valsartan is a sodium salt complex comprising sacubitril (AHU377), a prodrug, which is further metabolized to the...

    Twitter Linkedin Facebook Pinterest Google plus
  • < vorige
page 

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
 of  17
  • volgende >

Filter by specialisme:

Volg Novartis

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
Sitemap
Cookie Settings
©2025 Novartis België en Luxemburg
  • Gebruiksvoorwaarden
  • Over cookies
Deze website is bestemd voor zorgverleners in België en Luxemburg